Magnuson William J, Petereit Daniel G, Anderson Bethany M, Geye Heather M, Bradley Kristin A
University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A.
John T. Vucurevich Cancer Care Institute, Rapid City, SD, U.S.A.
Anticancer Res. 2015 Jan;35(1):365-70.
BACKGROUND/AIM: The optimal adjuvant therapy for stage I uterine sarcoma remains unresolved and may consist of radiotherapy (RT), chemotherapy, hormonal therapy or observation. We analyzed the impact of adjuvant pelvic RT on overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), pelvic control (PC) and patterns of failure.
A retrospective analysis of 157 patients with International Federation of Gynecology and Obstetrics FIGO stage I uterine sarcoma was performed. RT was given postoperatively to a dose of 45-51 Gy in 28-30 fractions.
The 5-year OS, CSS, DFS and PC was 58%, 62%, 47% and 72%, respectively. Adjuvant RT significantly improved PC (85% for RT group vs. 64% for non-RT group; p=0.02) but did not impact OS, CSS or DFS.
The addition of adjuvant pelvic RT significantly improved PC for patients with stage I uterine sarcoma. As systemic therapies continue to improve, optimal locoregional control may result in improved patient outcomes.
背景/目的：I期子宫肉瘤的最佳辅助治疗方案仍未确定，可能包括放射治疗（RT）、化疗、激素治疗或观察。我们分析了辅助盆腔放疗对总生存期（OS）、特定病因生存期（CSS）、无病生存期（DFS）、盆腔控制（PC）和失败模式的影响。
对157例国际妇产科联盟（FIGO）I期子宫肉瘤患者进行回顾性分析。术后给予放疗，剂量为45 - 51 Gy，分28 - 30次进行。
5年总生存期、特定病因生存期、无病生存期和盆腔控制率分别为58%、62%、47%和72%。辅助放疗显著提高了盆腔控制率（放疗组为85%，非放疗组为64%；p = 0.02），但对总生存期、特定病因生存期或无病生存期没有影响。
对于I期子宫肉瘤患者，添加辅助盆腔放疗可显著提高盆腔控制率。随着全身治疗的不断改善，最佳的局部区域控制可能会改善患者的预后。
